AR092356A1 - Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion - Google Patents
Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacionInfo
- Publication number
- AR092356A1 AR092356A1 ARP130102609A ARP130102609A AR092356A1 AR 092356 A1 AR092356 A1 AR 092356A1 AR P130102609 A ARP130102609 A AR P130102609A AR P130102609 A ARP130102609 A AR P130102609A AR 092356 A1 AR092356 A1 AR 092356A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation
- rosuvastatin
- oral administration
- preparation
- coating layer
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003105 metformin Drugs 0.000 title abstract 2
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title abstract 2
- 229960000672 rosuvastatin Drugs 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000011247 coating layer Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Una formulación compuesta para administración oral, que comprende: 1) un núcleo de liberación prolongada que comprende metformina o una de sus sales aceptables desde el punto de vista farmacéutico, y un agente de control de liberación; 2) una primera capa de recubrimiento formada sobre una superficie del núcleo, que comprende un material de recubrimiento funcional; y 3) una segunda capa de recubrimiento formada sobre una superficie de la primera capa de recubrimiento, que comprende rosuvastatina o una de sus sales aceptables desde el punto de vista farmacéutico y un agente de alcalinización.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120080347A KR20140013436A (ko) | 2012-07-24 | 2012-07-24 | 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092356A1 true AR092356A1 (es) | 2015-04-15 |
Family
ID=49223464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102609A AR092356A1 (es) | 2012-07-24 | 2013-07-23 | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion |
Country Status (5)
| Country | Link |
|---|---|
| KR (1) | KR20140013436A (es) |
| AR (1) | AR092356A1 (es) |
| TW (1) | TWI573587B (es) |
| UY (1) | UY34931A (es) |
| WO (1) | WO2014017833A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY181172A (en) * | 2014-06-30 | 2020-12-21 | Hanmi Pharm Ind Co Ltd | Composite preparation comprising active ingredient-containing film coating layer |
| PL3150201T3 (pl) * | 2014-06-30 | 2020-09-21 | Hanmi Pharm. Co., Ltd. | Preparat kompozytowy zawierający błonową warstwę powlekającą zawierającą inhibitor 5-reduktazy i sposób wytwarzania preparatu kompozytowego |
| BR112016030731A2 (pt) * | 2014-06-30 | 2017-08-22 | Hanmi Pharm Ind Co Ltd | Preparação de compósito, e, método de preparação de uma preparação de compósito |
| CN104523650B (zh) * | 2014-12-20 | 2017-04-12 | 山东新时代药业有限公司 | 一种含有瑞舒伐他汀钙的胶囊 |
| KR101526825B1 (ko) * | 2014-12-23 | 2015-06-08 | 주식회사 한독 | 당뇨병 치료용 약제학적 조성물 |
| KR102055894B1 (ko) * | 2016-11-15 | 2019-12-13 | 주식회사 엘지화학 | 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제 |
| KR102687535B1 (ko) * | 2018-07-06 | 2024-07-24 | 한미약품 주식회사 | 무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050013863A1 (en) * | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
| MX2011011480A (es) * | 2009-05-01 | 2012-02-28 | Aptalis Pharmatech Inc | Composicines de tabletas que se desintegran oralmente que comprenden combinaciones de analgesicos no opioides y opioides. |
| WO2011049309A2 (ko) * | 2009-10-09 | 2011-04-28 | 영진약품공업 주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| WO2011081493A2 (en) * | 2009-12-30 | 2011-07-07 | Bcworld Pharm. Co., Ltd. | Pharmaceutical composition comprising metformin and rosuvastatin |
-
2012
- 2012-07-24 KR KR1020120080347A patent/KR20140013436A/ko not_active Withdrawn
-
2013
- 2013-07-23 AR ARP130102609A patent/AR092356A1/es unknown
- 2013-07-23 TW TW102126262A patent/TWI573587B/zh not_active IP Right Cessation
- 2013-07-23 UY UY0001034931A patent/UY34931A/es not_active Application Discontinuation
- 2013-07-24 WO PCT/KR2013/006637 patent/WO2014017833A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140013436A (ko) | 2014-02-05 |
| TWI573587B (zh) | 2017-03-11 |
| WO2014017833A1 (en) | 2014-01-30 |
| UY34931A (es) | 2013-09-02 |
| TW201408283A (zh) | 2014-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
| CO2020000490A2 (es) | Preparación que comprende vonoprazán | |
| CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
| AR088232A1 (es) | Composiciones farmaceuticas | |
| DOP2017000306A (es) | Formulaciones farmacéuticas que contienen tenofovir y emtricitabina | |
| UY35586A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| AR104257A1 (es) | Tableta de ribociclib | |
| DOP2016000024A (es) | Comprimido farmacéutico que comprende ácido acetilsalicílico y clopidogrel | |
| CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
| AR098417A1 (es) | Formulación farmacéutica combinada que comprende amlodipina, losartán y rosuvastatina | |
| MX2017007699A (es) | Formulacion de proporcion fija de insulina glargina/lixisenatida. | |
| MX386808B (es) | Sistema de suministro de fármaco que comprende un resto de hidrazona y un enlace amida para proporcionar liberción controlada de agentes terapéuticos | |
| UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
| CL2018001590A1 (es) | Composiciones farmacéuticas que comprenden algun derivado de fenilaminopirimidina. | |
| CL2012003341A1 (es) | Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades. | |
| PE20150721A1 (es) | Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion | |
| DOP2013000024A (es) | Composicion farmaceutica de liberacion prolongada de trimetazidina | |
| MX2019004938A (es) | Cápsula compleja que contiene esomeprazol y método de preparación de esta. | |
| MX2015012970A (es) | Formas de dosificacion solidas de liberacion prolongada antiemeticas. | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| CO2018002046A2 (es) | Nueva composición oral de libreación retardada dual de dexlansoprazol | |
| AR097202A1 (es) | Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa | |
| MX2019014687A (es) | Formulaciones farmaceuticas orales de remogliflozina. | |
| ES2680293B1 (es) | Composición farmacéutica que comprende ácido 2,5 - dihidroxibencenosulfónico o una de sus sales farmacéuticamente aceptables en forma de unidades individualizadas de suministro y procedimiento de fabricación correspondiente | |
| ES2561813T3 (es) | Aplicación tópica de nimesulida y tiocolchicósido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |